This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

**Active Ingredient:** Indacaterol maleate

**Dosage Form; Route:** Powder; Inhalation

**Strength:** EQ 0.075 mg Base/inh

**Recommended Studies:** Two in vitro bioequivalence studies, one in vivo bioequivalence study with pharmacokinetic endpoints, and one comparative clinical endpoint bioequivalence study

FDA recommends the following in vitro and in vivo studies to establish bioequivalence of the test (T) and reference (R) dry powder inhalers (DPIs) containing indacaterol maleate.

**In vitro bioequivalence studies:**

FDA recommends that prospective applicants conduct the following in vitro bioequivalence studies for the T and R products. Use at least three batches each of T and R products, with no fewer than 10 units from each batch. FDA recommends that three primary stability batches be also used to demonstrate in vitro bioequivalence. The three batches of T product should be manufactured from, at minimum, three different batches of drug substance(s), excipient(s), and device constituent part components. The T product should consist of the final device constituent part and final drug constituent formulation intended to be marketed.
1. **Type of study:** Single actuation content (SAC)  
   **Design:** The SAC test should be performed at the beginning (B), middle (M), and end (E) life stages\(^1,2\) of the product using flow rates of 30 L/min, 60 L/min and 90 L/min. U.S. Pharmacopeia (USP) \(<601>\) Apparatus B or another appropriate apparatus may be used to determine the SAC using a validated assay. The number of capsule and the number of actuation per capsule used per determination should be one. The volume of air drawn through the delivery system per actuation should be 2 L.  
   **Equivalence based on:** Population bioequivalence (PBE) analysis of SAC. Refer to the most recent version of the FDA product-specific guidance for *Budesonide Inhalation Suspension*\(^a\) for additional information regarding PBE analysis procedure.

2. **Type of study:** Aerodynamic particle size distribution (APSD)  
   **Design:** The APSD test should be performed at the B and E lifestages of the product using flow rates of 28.3 L/min or 30 L/min, 60 L/min and 90 L/min. Cascade impaction devices as per USP \(<601>\) Table 2 or another appropriate method may be used to determine APSD using a validated assay. The APSD determination of each unit should be performed with a minimum number of capsules justified by the sensitivity of the validated assay. The volume of air drawn through the delivery system should be 4 L.  
   **Additional comments:** Drug deposition on individual sites, including the mouthpiece adapter, the induction port, the pre-separator, and each stage of the cascade impactor (CI) and the filter, is requested. Mass balance accountability should be reported based on the sum of all deposition sites. For electronic submission of the individual CI data for the T and R products, please provide a table using the format in the appendix, and send them as part of the abbreviated new drug application (ANDA) submission for bioequivalence evaluation.  
   **Equivalence based on:** PBE analysis of impactor-sized mass (ISM).\(^3\) The CI profiles representing drug deposition on the individual stages of the CI along with the mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD) and fine particle mass (FPM) should be submitted as supportive evidence for equivalent APSD.

---

\(^1\) Based on the labeled number of actuations, the terms, B life stage, M life stage, and E life stage represent the first actuation(s), the actuation(s) corresponding to 50 percent of the labeled number of actuations, and the actuation(s) corresponding to the labeled number of actuations, respectively. In vitro lifestage testing should be conducted on the to be marketed packaging configuration with the highest number of doses. For example, the B, M, and E lifestage for a 30 capsule packaging configuration may correspond to actuations 1, 15, and 30.

\(^2\) When conducting in vitro studies at different lifestages, doses between those tested at each lifestage should be actuated using the device. For example, prospective applicants testing at the E lifestage should actuate all doses leading up to the dose used to test the E lifestage.

\(^3\) ISM is defined as a sum of the drug mass on all stages of the CI plus the terminal filter, but excluding the top CI stage because of its lack of a specified upper cut-off size limit.
In vivo bioequivalence study with pharmacokinetic endpoints:

FDA recommends that prospective applicants conduct the following pharmacokinetic bioequivalence study for the T and R products.

1. Type of Study: Fasting  
   Design: Single-dose, two-way crossover  
   Dose: Minimum number of inhalations that is sufficient to characterize a pharmacokinetic profile by using a sensitive analytical method  
   Subjects: Healthy males and non-pregnant females  
   Additional comments: (1) Subjects enrolled for in vivo studies should be trained in the use of the inhalation powder in a standard fashion prior to each treatment session to assure a relatively consistent inspiratory flow rate and inspiratory duration. (2) A Bio-IND is required prior to conduct of the pharmacokinetic study if the dose exceeds the maximum labeled single dose.

Analyte to measure: Indacaterol in serum

Equivalence based on: AUC and C_{max} for indacaterol. The 90% confidence intervals for the geometric mean T/R ratios of AUC and C_{max} should fall within the limits of 80.00% - 125.00%.

Comparative clinical endpoint bioequivalence study:

FDA recommends that prospective applicants conduct the following comparative clinical endpoint bioequivalence study for the T and R products.

1. Type of Study: Comparative clinical endpoint bioequivalence study  
   Design: This study could be either of crossover or parallel-group design, taking into consideration the patient population and the current standard-of-care treatment for chronic obstructive pulmonary disease (COPD), and should include appropriate justification for the design chosen. The study should be randomized, single-dose, blinded (where possible) and placebo-controlled, at minimum consisting of a 2-week run-in period (to allow for washout) followed by a one-day treatment period of the placebo, T, or R product.  
   Strength: EQ 0.075 mg Base/inh (indacaterol maleate inhalation powder)  
   Dose: EQ 0.075 mg indacaterol, single-dose  
   Subjects: Males and non-pregnant females with COPD. The study may enroll all COPD patients who meet the inclusion and exclusion criteria, or may be enriched with patients who demonstrate ≥ 15% reversibility to bronchodilator therapy (appropriate justification should be included for the population chosen for the study).
Inclusion and exclusion criteria:

a. Inclusion criteria should, at minimum, include:
   - Adult (≥ 40 y. o.) male or female subjects of non-child-bearing potential or of child-bearing potential but committed to consistent use of an acceptable method of birth control
   - Diagnosis of COPD, as defined by American Thoracic Society (ATS) [GOLD criteria]
   - Post-bronchodilator forced expiratory volume in one second (FEV1) ≤ 80%
   - Post-bronchodilator FEV1/forced vital capacity (FVC) ratio ≤ 0.70
   - Current or former smokers (e.g., with history of at least 10 pack-years)
   - Willingness to give their written informed consent to participate in the study

b. Exclusion criteria should, at minimum, include:
   - Known respiratory disorders other than COPD including, but not limited to the following: alpha-1 antitrypsin deficiency, cystic fibrosis, significant asthma, active bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, pulmonary edema, or interstitial lung disease
   - Evidence or history of other clinically significant disease or abnormality (such as congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, stroke, glaucoma, or cardiac dysrhythmia), which, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study
   - Known active tuberculosis
   - History of allergy or hypersensitivity to beta-2 adrenergic agonists, or to drugs from similar chemical classification, including untoward reactions to sympathomimetic amines or known hypersensitivity to any of the proposed ingredients or components of the delivery system
   - Hospitalization for COPD or pneumonia within 12 weeks prior to initiation of the study
   - Treatment of COPD exacerbation within 12 weeks prior to study
   - Inability to discontinue COPD medications during the run-in and treatment periods
   - Acute (viral or bacterial) upper or lower respiratory tract infection, sinusitis, rhinitis, pharyngitis, urinary tract infection or illness within six weeks prior to screening
   - Abnormal and significant ECG finding prior to the screening, during the run-in and treatment periods
   - Lung volume reduction surgery within the previous 12 months
   - Chronic oxygen use for >12 hours/day
Additional comments:

a. A clear list of permitted and restricted medications should be provided, including justification for use (or restriction) of certain classes of respiratory therapies, that considers the current standard-of-care for COPD.

b. All spirometry should be conducted in accordance with ATS standards.

c. The study protocol should list appropriate withholding times prior to spirometry for permitted concomitant medications (e.g., 4 hours for short-acting beta-agonists, 12 or 24 hours for long-acting beta-agonists).

d. The study should begin with a placebo run-in period (at least two weeks in duration; appropriate justification should be included for the duration chosen) to washout any pre-study long-acting bronchodilators or anticholinergic agents and to establish FEV₁ baseline values.

e. To ensure adequate study sensitivity, the T and R products should both be statistically superior to placebo (p < 0.05) with regard to the BE study primary endpoint.

f. It is the prospective applicant’s responsibility to enroll a sufficient number of subjects for the study to demonstrate BE of the T to the R product.

g. All adverse events (AEs) should be reported whether or not they are considered to be related to the treatment. The report of AEs should include date of onset, description of the AE, severity, relation to study medication, action taken, outcome and date of resolution.

h. Appropriate pre-defined withdrawal criteria should be described for patients who may require withdrawal during washout period due to COPD exacerbation or inability to tolerate withdrawal of baseline therapy.

i. Subjects who discontinued from the study early should be identified, and the protocol should clearly, prospectively state how missing data will be handled in the statistical analyses and provide appropriate justification for the method chosen. The protocol should also include subject retention strategies and other plans to minimize missing data. If there are missing data, adequate justification should be provided that the missing data do not lead to biased equivalence determination. Detailed information for all subjects who are discontinued from the study should be provided.

**Bioequivalence study primary endpoint:** Area under the serial FEV₁-time curve calculated from time zero to 24 hours (AUC⁰⁻₂₄h) following the treatment.

The above BE study endpoint should be baseline-adjusted (change from baseline). FEV₁ measurements should be performed and interpreted in accordance with ATS guidelines.

Serial spirometry (FEV₁) should be measured at 0, 5 and 30 min, 1, 2, 4, 6, 8, 10, 12, 23 and 24 hours post-dose.

For each treatment group, time to peak bronchodilator response (Tmax) and FEV₁ values at all measurement times within each evaluation period should be included in the final study report.
**Equivalence based on:** T/R ratio for the primary endpoint. The 90% confidence intervals for the T/R ratios for the study endpoint should fall within 80.00% - 125.00%.

**Additional information:**

**Formulation:**
The T product is recommended to be qualitatively (Q₁)⁴ and quantitatively (Q₂)⁵ the same as the R product. If a prospective applicant uses a Q₂-different formulation for its T product, the prospective applicant should explain the reason(s) for not using a T formulation that is Q₂ the same as the R formulation. In addition, the prospective applicant should provide pharmaceutical development data, involving in vitro testing of multiple drug-to-excipient ratios that encompass combinations below and above the ratios used in the T and R products.

**Device:**
The reference listed drug (RLD) is presented in drug capsules co-packaged with a dry powder inhaler. The inhaler is the device constituent part.

FDA recommends that prospective applicants examine the size and shape, the external critical design attributes, and the external operating principles of the RLD device when designing the test devices including:
- Passive (breath-actuated), pre-metered, single-unit dose, capsule-based format of the RLD device
- Number of doses of the RLD product
- Device resistance of the RLD product

**User interface assessment:**
An ANDA for this product should include complete comparative analyses so FDA can determine whether any differences in design for the user interface of the proposed generic product, as compared to the RLD, are acceptable and whether the product can be expected to have the same clinical effect and safety profile as the RLD when administered to patients under the conditions specified in the labeling. For additional information, refer to the most recent version of the FDA guidance for industry on *Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA.* ⁶

---

⁴ Q₁ (qualitative sameness) means that the test product uses the same inactive ingredient(s) as the reference product.
⁵ Q₂ (quantitative sameness) means that concentrations of the inactive ingredient(s) used in the test product are within ± 5% of those used in the reference product.
**APPENDIX**

<table>
<thead>
<tr>
<th>Variable Name</th>
<th>Variable Type</th>
<th>Content</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Name</td>
<td>Character</td>
<td>TEST or REF</td>
<td>Identifier for product</td>
</tr>
<tr>
<td>LOT Number</td>
<td>Alphanumeric/Numeric</td>
<td>Alphanumeric/Numeric</td>
<td>Identifier for product lot</td>
</tr>
<tr>
<td>UNIT Number</td>
<td>Numeric</td>
<td>Numeric values</td>
<td>Identifier for unit must be unique for each product (e.g. #1-30 for test and #31-60 for ref).</td>
</tr>
</tbody>
</table>

| Stage 1       | Numeric               | Numeric Values| S1                                                                   |
| Stage 2       | Numeric               | Numeric Values| S2                                                                   |
| Stage 3       | Numeric               | Numeric Values| S3                                                                   |
| Stage 4       | Numeric               | Numeric Values| S4                                                                   |
| Stage 5       | Numeric               | Numeric Values| S5                                                                   |
| Stage 6       | Numeric               | Numeric Values| S6                                                                   |
| Stage 7       | Numeric               | Numeric Values| S7                                                                   |
| Stage 8 or Filter | Numeric     | Numeric Values| S8                                                                   |
| ISM           | Numeric               | Numeric Values| ISM                                                                  |
| MMAD          | Numeric               | Numeric Values| MMAD                                                                 |
| GSD           | Numeric               | Numeric Values| GSD                                                                  |
| FPM           | Numeric               | Numeric Values| FRM                                                                  |

Example:

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>LOT</th>
<th>Unit</th>
<th>S1</th>
<th>S2</th>
<th>S3</th>
<th>S4</th>
<th>S5</th>
<th>S6</th>
<th>S7</th>
<th>S8 or Filter</th>
<th>ISM</th>
<th>MMAD</th>
<th>GSD</th>
<th>FPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEST</td>
<td>1234</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>